Blood Res 2013; 48(4):
Published online December 31, 2013
https://doi.org/10.5045/br.2013.48.4.266
© The Korean Society of Hematology
1Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
2Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Correspondence to : Correspondence to Jooryung Huh, M.D., Ph.D. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Seoul 138-736, Korea. Tel: +82-2-3010-4553, Fax: +82-2-472-7898, jrhuh@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathological entity, and its molecular classification into germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes using gene expression profile analysis has been shown to have prognostic significance. Recent attempts have been made to find an association between immunohistochemical findings and molecular subgroup, although the clinical utility of immunohistochemical classification remains uncertain.
The clinicopathological features and follow-up data of 68 cases of surgically resected gastrointestinal DLBCL were analyzed. Using the immunohistochemical findings on tissue microarray, the cases were categorized into GCB and non-GCB subtypes according to the algorithms proposed by Hans, Muris, Choi, and Tally.
The median patient age was 56 years (range, 26-77 years). Of the 68 cases included, 39.7% (27/68) involved the stomach, and 60.3% (41/68) involved the intestines. The GCB and non-GCB groups sorted according to Hans, Choi, and Tally algorithms, but not the Muris algorithm, were closely concordant (Hans vs. Choi, κ=0.775,
The Hans, Choi, and Tally algorithms might represent identical DLBCL subgroups, but this grouping did not correlate with prognosis. Further studies may delineate the association between immunohistochemical subgroups and prognosis.
Keywords Diffuse large B-cell lymphoma, Gastrointestinal tract, Immunohistochemistry, Prognosis
Blood Res 2013; 48(4): 266-273
Published online December 31, 2013 https://doi.org/10.5045/br.2013.48.4.266
Copyright © The Korean Society of Hematology.
Hee Sang Hwang1, Dok Hyun Yoon2, Cheolwon Suh2, Chan-Sik Park1, and Jooryung Huh1*
1Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
2Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Correspondence to:Correspondence to Jooryung Huh, M.D., Ph.D. Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Seoul 138-736, Korea. Tel: +82-2-3010-4553, Fax: +82-2-472-7898, jrhuh@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathological entity, and its molecular classification into germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes using gene expression profile analysis has been shown to have prognostic significance. Recent attempts have been made to find an association between immunohistochemical findings and molecular subgroup, although the clinical utility of immunohistochemical classification remains uncertain.
The clinicopathological features and follow-up data of 68 cases of surgically resected gastrointestinal DLBCL were analyzed. Using the immunohistochemical findings on tissue microarray, the cases were categorized into GCB and non-GCB subtypes according to the algorithms proposed by Hans, Muris, Choi, and Tally.
The median patient age was 56 years (range, 26-77 years). Of the 68 cases included, 39.7% (27/68) involved the stomach, and 60.3% (41/68) involved the intestines. The GCB and non-GCB groups sorted according to Hans, Choi, and Tally algorithms, but not the Muris algorithm, were closely concordant (Hans vs. Choi, κ=0.775,
The Hans, Choi, and Tally algorithms might represent identical DLBCL subgroups, but this grouping did not correlate with prognosis. Further studies may delineate the association between immunohistochemical subgroups and prognosis.
Keywords: Diffuse large B-cell lymphoma, Gastrointestinal tract, Immunohistochemistry, Prognosis
Examples of partially positive staining for each immunohistochemical marker.
Summary of the
Kaplan-Meier survival analyses with respect to the
Table 1 . Primary antibodies used for immunohistochemical staining and their dilution..
Table 2 . Baseline characteristics of assigned cases (N=68)..
a)Log-rank test. b)Statistically significant parameters..
Abbreviations: IPI, international prognostic index; LDH, lactate dehydrogenase..
Table 3 . Scoring of the different immunohistochemistry stains using individual antibodies..
a)Results according to the Hans algorithm criteria (nuclear staining ≥30%). b)Results according to the Choi algorithm criteria (nuclear staining ≥80%)..
Table 4 . Cross-table analysis of the distribution of the GCB and non-GCB subtypes according to 3 different algorithms..
Abbreviation: GCB, germinal center B-cell-like..
Table 5 . The concordance rate and degrees of agreement between all the 4 algorithms in the gastrointestinal diffuse large B-cell lymphomas..
a)Substantial agreement. b)Moderate agreement..
Table 6 . Immunohistochemistry profiles of discrepant cases: Hans versus Choi algorithms..
Abbreviation: GCB, germinal center B cell-like..
Table 7 . Immunohistochemistry profiles of discrepant cases: Hans versus Tally algorithms..
Abbreviation: GCB, germinal center B cell-like..
Table 8 . Univariate survival analyses of immunohistochemical markers and algorithms..
a)From Lugano stage I to IIE. b)Log-rank test. c)Results according to the criterion for Hans algorithm (nuclear staining ≥30%). d)Results according to the criterion for Choi algorithm (nuclear staining ≥80%). e)Borderline significant parameter (
Abbreviations: OS, overall survival; PFS, progression-free survival..
Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, Xiaona Niu, Kai Sun
Blood Res 2023; 58(4): 187-193Junshik Hong, Sojung Lee, Gayoung Chun, Ji Yong Jung, Jinny Park, Jeong Yeal Ahn, Eun Kyung Cho, Dong Bok Shin, and Jae Hoon Lee
Blood Res 2016; 51(2): 113-121Shuku Sato, Shun Tsunoda, Wataru Kamata, Tomiteru Togano and Yotaro Tamai
Blood Res 2025; 60():
Examples of partially positive staining for each immunohistochemical marker.
Summary of the
Kaplan-Meier survival analyses with respect to the